From: Magnetic resonance imaging is effective for evaluating the therapeutic effect of tolvaptan on total kidney volume in patients with autosomal dominant polycystic kidney disease
Protein uria
< 0.15 g/gCr
0.15-0.49 g/gCr
> 0.50 g/gCr
CKD stage
GFR (mL/min/1.73m2)
≧90
120 (case 1)
60~ 89
45~ 59
90/90 (case 2 and 3)
30~ 44
120/90 (case 4 and 5)
15~ 29
90 (case 6)
< 15
(mg/day)